Floatz logo

cd19-ucart

Safety and Efficacy of CD19 UCAR-T Cells

Shanghai Longyao Biotechnology Inc., Ltd.Cell therapyEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Safety and Efficacy of CD19 UCAR-T Cells cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

cd19-ucart is also rated in:

B-Cell Acute Lymphoblastic Leukemia, AdultDormant
BBB
Indicative ·
72 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →